Business
Result of General Meeting
Result of General Meeting.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n7 April 2025\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nResult of General Meeting\nand\nTotal voting Rights\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the general meeting of the Company, held earlier today, all resolutions were duly passed.\n \nFollowing the passing of the resolutions, the Company has raised a total of approximately £1.17 million pursuant to the Placing, details of which were announced on 18 March 2025.\n \nApplication has been made for admission of the 8,416,020 Second Tranche Placing Shares to trading on AIM (\"Admission\"). It is currently anticipated that Admission will become effective and that dealings in the Second Tranche Placing Shares will commence on AIM at 8.00 a.m. on 9 April 2025.\n \nTotal voting rights\n \nOn Admission, the Company will have 113,318,140 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 113,318,140 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \nUnless otherwise defined herein, the capitalised defined terms used in this announcement have the same meaning as those used in the Company's announcement on 18 March 2025.\n \nNavigate to our Interactive Investor hub here: https://investorhub.fusionantibodies.com/. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\n \nEnquiries: \n \n\n\n\n\nInvestor questions on this announcement\n\n\nInvestor hub\n\n\n\n\nWe encourage all investors to share questions\n\n\n\n\n\n\n\non this announcement via our investor hub\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFusion Antibodies plc\n\n\n www.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n \n\n\n\n\n\...